On March 8, 2022 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, reported publication of four abstracts featuring preclinical data from its expanding pipeline in advance of the AACR (Free AACR Whitepaper) Annual Meeting 2022 in New Orleans, Louisiana from April 8-13, 2022 (Press release, Adagene, MAR 8, 2022, View Source [SID1234609780]). The full abstracts are available on the AACR (Free AACR Whitepaper) meeting website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At AACR (Free AACR Whitepaper), presentations will include preclinical results showing the potential best-in-class profiles for three differentiated preclinical product candidates in IND-enabling studies: ADG138, ADG206 and ADG153. The fourth presentation introduces a new capability for the company’s proprietary bispecific T-cell engagers (TCEs) with CD28.
Details for the poster presentations include:
·Title: ADG138, A Novel HER2×CD3 POWERbody Integrating Bispecific TCE with Precision Masking to Control Cytokine Release Syndrome and On-Target Off-Tumor Toxicity for Single Agent and Combination Therapies in HER2-Expressing Solid Tumors
Date: Tuesday April 12, 2022
Poster Session: 9:00 a.m. – 12:30 p.m. ET
Onsite Location: Exhibit Halls D-H, Poster Section 37
Abstract Number: 2869
·Title: ADG206, an anti-CD137 agonistic POWERbodyTM with tailor-made efficacy and safety profiles by strong crosslinking and tumor selective activation for single agent and combinational cancer immunotherapy
Date: Tuesday, April 12, 2022
Poster Session: 9:00 a.m. – 12:30 p.m. ET
Onsite Location: Exhibit Halls D-H, Poster Section 37
Abstract Number: 2868
·Title: Tumor-targeted CD28 bispecific POWERbodyTM for safe and synergistic T cell-mediated immunotherapy
Date: Tuesday, April 12, 2022
Poster Session: 9:00 a.m. – 12:30 p.m. ET
Onsite Location: Exhibit Halls D-H, Poster Section 38
Abstract Number: 2888
·Title: ADG153-G1 SAFEbody, a differentiated masked anti-CD47 antibody of IgG1 subclass, demonstrates in vivo anti-tumor activity consistent with enhanced ADCC/ADCP effects and significantly reduced RBC-related and antigen sink liabilities
Date: Wednesday, April 13, 2022
Poster Session: 9:00 a.m. – 12:30 p.m. ET
Onsite Location: Exhibit Halls D-H, Poster Section 39
Abstract Number: 4257
"These presentations highlight the promise of our AI-driven technology platform to build a deep, broad, and differentiated pipeline of transformative antibody therapeutics," said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. "Our ‘three-body’ technologies are well suited to discover and engineer antibody-based modalities against clinically important targets such as HER2, TROP2, B7H3, CD137, CD47 and CD28, overcoming challenges of prior platform technologies, validated by clinical data from our ongoing clinical programs, and endorsed by our strategic partnerships with global pharmaceutical and biopharmaceutical companies."
Dr. Luo continued, "We are designing safe and effective antibody candidates across the cancer immunity cycle, including our POWERbody approach, which integrates the SAFEbody technology with multiple antibody-based modalities. These include ADG138, a new HER2xCD3 bispecific TCE for solid tumors, and ADG206, an Fc engineered anti-CD137 therapy, both designed for enhanced safety and efficacy. Additionally, we are establishing a new paradigm for CD28 TCEs by putting all the pieces together to ensure ultimate safety and mitigate known risks of this target – a unique, highly conserved epitope, our precision masking technology and a tumor antigen targeted TCE for local activation. With these novel therapeutic approaches, we aim to push the boundaries of what is possible with TCEs – to achieve safe, potent and durable responses for solid tumors."